Abstract
High-risk and locally advanced prostate cancer (PCa) patients are likely to undergo multimodality treatment. Patients should at all times be fully informed about all available options and the likelihood of a multimodal approach, including the potential side effects of both local and systemic treatment. For high-risk localized and locally advanced PCa, both radical prostatectomy as part as multimodal therapy and external beam radiotherapy (EBRT) + long-term androgen deprivation therapy (ADT) can be recommended as primary treatment. For high-risk localized PCa, EBRT + BT can also be offered despite a less favorable toxicity profile. In selected high-risk PCa patients, a shorter duration of ADT might be considered. Until the results of the SPCG15 trial are known, the optimal local treatment remains a matter of debate.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 614-627 |
| Number of pages | 14 |
| Journal | European Urology |
| Volume | 77 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2020 |
Bibliographical note
Funding Information:Financial disclosures: Lisa Moris certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Professor Dr. D. Tilki received speaker honorarium from Astellas and a travel grant from Janssen. Dr. E. Briers has received grant and research support from IPSEN, the European Association of Urology, and Bayer; is an ex officio board member for Europa UOMO; is an ethics committee and advisory group member for REQUITE; is a patient advisory board member for PAGMI; and is a member of SCA and EMA PCWP. Professor Gillessen has served on advisory boards for Orion, Innocrin, Clovis, Bayer, AAA International, Roche, Menarini, Sanofi, and ProteoMedix; receives company speaker honorarium from Janssen; and has served on the IDMC for Janssen. Professor Dr. J.P. Grummet received speaker honorarium from Mundipharma, a travel grant from Astellas, and a research grant from Cancer Australia; and is the owner of MRI PRO Pty Ltd., an online training platform. Professor Dr. A.M. Henry participates in trials by Cancer Research UK and the National Institute of Health Research; her department receives research grants from Cancer research UK, The Medical Research Council, and the National Institute of Health. Professor Dr. M. De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc., ESSA, Ferring, GSK, Incyte, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials run by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc., Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SOTIO, and Cancer Research UK; participates in various trials as a member of the EORTC GU group; and has received research grants from Pierre Fabre Oncologie, and travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreaon, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Professor Dr. M.D. Mason is a company consultant for Ellipses Pharma and Oncotherics. Professor Dr. H.G. van der Poel is a company consultant for Intuitive Surgical; has participated in trials for Astellas and Steba Biotech; and has received grant and research support from Astellas. Professor Dr. S. Fanti is a company consultant for Bayer and ANMI; has received speaker honorarium from Bayer, Genzyme, ANMI, and GE Healthcare; and participates in trials by Amgen, Bayer, BMS, Genzyme, Janssen, Merck, and Novartis. Dr. T.B.L. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and IPSEN. Professor Dr. P. Cornford is a company consultant for Astellas, IPSEN, and Ferring; receives company speaker honoraria from Astellas, Janssen, IPSEN, and Pfizer; participates in trials run by Ferring; and receives fellowships and travel grants from Astellas and Janssen. Professor Dr. N. Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, IPSEN, Sanofi, Janssen, and Roche. Professor Dr. T. Wiegel is an advisory board member for IPSEN; receives company speaker honoraria from IPSEN and Hexal; is a member of the Janssen Steering Committee; and has participated in the ATLAS/AUO trial. Dr. L. Moris, Dr. M.G. Cumberbatch, Dr. G. Gandaglia, Dr. N. Fossati, Dr. B. Kelly, Dr. R. Pal, Dr. T. Van den Broeck, Dr. R.C.N. van den Bergh, Dr. M.I. Omar, Dr. M. Lardas, Dr. M. Liew, Professor Dr. O. Rouvière, Dr. I.G. Schoots, Professor Dr. T.H. van Der Kwast, Dr. P-P. M. Willemse, Dr. C.Y. Yuan, Professor Dr. B. Konety, Professor Dr. T. Dorff, and Professor Dr. S. Jain have nothing to declare.
Publisher Copyright:
© 2020 European Association of Urology
Keywords
- Brachytherapy
- External beam radiotherapy
- Localized
- Locally advanced
- Modality treatment
- Primary therapy
- Prostate cancer
- Radical prostatectomy
- Systematic review
- Systemic treatment
